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Two common variants, close from TTF-1 and TTF-2, were shown to predispose to thyroid cancer (TC) in European populations.
WeaimedtoinvestigatewhetherTTF-1andTTF-2variantsmightcontributetoTCearlyonset(EO).Tumorsamplesfromeighteen
patients with papillary TC (PTC), who underwent total thyroidectomy at an age of ≤21, were screened for TTF-1 and TTF-2
variants. No TTF-1variants were documented; two novel germinal TTF-2variants, c.200C>G (p.A67G) and c.510C>A (p.A170A),
were identiﬁed in two patients. Two already described TTF-2 variants were also documented; the allelic frequency among patients
was not diﬀerent from that observed among controls. Moreover, RET/PTC rearrangements and the BRAFV600E mutation were
identiﬁed in 5/18 and 2/18 PTCs, respectively. Thyroglobulin (TG) and thyroid peroxidase (TPO) expression was found to be
signiﬁcantly decreased in tumors, and the lowest level of TPO expression occurred in a tumor harboring both the p.A67GTTF-2
variant and a RET/PTC3 rearrangement.
1.Introduction
Thyroid cancer is not common among children and adoles-
cents. Between 1975 and 2000, thyroid cancer represented
approximately 7.8% of all cancers diagnosed in the 15- to
19-year age group according to data in the Surveillance
Epidemiology and End Results (SEERs) database [1]. It is
very rare in children younger than 15 years of age with very
few cases diagnosed before 10 years of age. Diﬀerentiated
thyroid cancer (DTC), that is, papillary (PTC) or follicular
thyroid cancer (FTC), accounts for the vast majority of cases
and medullary thyroid cancer (MTC) accounts for the most
of the rest. Poorly diﬀerentiated and anaplastic cancers are
exceedingly rare.
Among environmental risk factors, a well-known risk
factor for PTC is exposure to ionizing radiation and for FTC
is deﬁciency in iodine intake. Common variants on 9q22.33
and 14q13.3 were shown to predispose to thyroid cancer in
European populations [2]. The gene nearest to the 9q22.33
locus is FOXE1 (TTF-2), and NKX2-1 (TTF-1) is among the
genes located at the 14q13.3 locus. Both genes are important
inthebiologyofthyroidgland,andtheirexpressionisaltered
in thyroid tumors [3, 4].
Based on the hypothesis that young patients are carriers
of genetic variants that inﬂuence their early onset of disease,
we analyzed samples from patients who developed thyroid
cancer early in life. Besides screening for the classical somatic
changes, known to cause neoplastic transformation, we
sought for TTF-1 and TTF-2 variants.
2.MaterialsandMethods
2.1. Patient Samples. Eighteen primary thyroid tumor sam-
ples from patients who underwent total thyroidectomy at
age ≤ 21 years (mean age, 14,1 ± 4,4yr; range, 5–21yr),
were analyzed. All were PTC. Exclusion criteria were prior2 Journal of Oncology
exposition to radiation or family history of thyroid disease.
Thirteen of these samples have already been included in a
previous study [5]. In seven cases, it was possible to pair
tumors with their normal adjacent tissue or contralateral
lobe. Peripheral blood samples from patients and 32 healthy
controls were also analyzed.
Tissue sample collection was carried out in accordance
with protocols approved by the institutional review board,
and informed consent was obtained for the study together
with the consent for surgery.
2.2. DNA, RNA Extraction, and cDNA Synthesis. Total RNA
wasobtained fromfrozentissuesusing TRizolreagent(Invit-
rogen, Paisley, UK), according to manufacturer’s instruc-
tions, and 2µg were reverse transcribed using random
primers and SuperScript II (Invitrogen). When applicable,
genomic DNA was extracted from peripheral blood lympho-
cytes using Puragene DNA Puriﬁcation System Blood Kit
(Gentra, USA).
2.3. Screening for BRAFV600E Mutation and RET/PTC Rear-
rangements. Screening for the BRAFV600E mutation and
RET/PTC rearrangements 1–3 was conducted as previously
described [6].
2.4. TTF-1/NKX2-1 and TTF-2/FOXE1 Variants Screen-
ing. The mutational analysis of TTF-1/NKX2-1 and TTF-
2/FOXE1 w a sp e r f o r m e di na l lt u m o rs a m p l e sb yR T -
PCR followed by direct sequencing. Two transcript variants
encoding diﬀerent protein isoforms have been described for
TTF-1/NKX2-1 gene. The transcript variant 1 (encoding the
longer protein isoform) was ampliﬁed using 6 overlapping
amplicons that encompass the 3 exons of its coding-
region. Similarly, 6 overlapping amplicons (5 of which
were common to both variants) were generated to span
the 2 exons that comprise the coding region of variant 2
(which encodes a shorter protein isoform with a N-terminus
distinct from isoform 1). The entire coding-region (a single
exon) of TTF-2/FOXE1 was also ampliﬁed by producing 6
overlapping amplicons. When appropriate, germline TTF-
2/FOXE1 alterations were screened in peripheral blood DNA
using analogous PCR conditions. Primers were designed
according to Gen-Bank sequence (GenBank accession num-
bers: NM 001079668 for TTF-1/NKX2-1 transcript variant
1, NM 003317 for TTF-1/NKX2-1 transcript variant 2, and
NM 004473 for TTF-2/FOXE1). The primer pairs used to
generate each amplicon, as well as the annealing temperature
and the amplicon expected length, are described in Table 1.
PCRpuriﬁedproductsweredirectlysequencedusingBigDye
Terminator v1.1 Cycle Sequencing kit (Applied Biosystems,
Foster City, CA).
2.5. QRT-PCR. The TPO and TG expression levels were
quantiﬁed by QRT-PCR, as previously described [5], on an
ABIPrism7900HTSequenceDetectionSystemusingspeciﬁc
primers and TaqMan probes from the Assay on Demand
products (Hs00174927 ml (TPO), Hs00794359 ml (TG);
Applied Biosystems). Ampliﬁcation reactions were per-
formed in triplicate for each sample, and the results were
normalized to endogenous GAPDH gene expression level
(Pre-Developed TaqMan Assay Reagents; P/N 4326317E;
Applied Biosystems).
2.6. Statistical Analysis. Statistical analysis was carried out
using GraphPad Prism statistical software (San Diego, CA).
When appropriate, values are expressed as mean ± SD. Sta-
tistical comparisons were made using the unpaired Student’s
t-test(two-tailed).StatisticalsigniﬁcancewasacceptedatP<
0.05 .
3. Results
3.1. Screening for RET/PTC Rearrangements, BRAFV600E
Mutation, and TTF-1/NKX2-1 and TTF-2/FOXE1 Variants.
RET/PTC rearrangementsandtheBRAFV600E mutationwere
identiﬁed in 5/18 and 2/18 PTCs, respectively (Table 2).
No TTF-1 variants were identiﬁed in tumors or in
controls. Two novel TTF-2 variants, c.200C>G (p.A67G)
and c.510C>A (p.A170A), were identiﬁed in heterozygosity
(Table2).Inbothcases,thevariantswerealsopresentincon-
stitutional DNA. In order to ascertain whether these variants
were polymorphisms, we analyzed samples from 32 controls.
The p.A170A variant was detected, in heterozygosity, in 1
control; none presented the p.A67G variant. In summary,
the p.A170A variant was detected in 2/100 alleles and the
p.A67Gvariantwasdetectedin1/100alleles(18patients+32
control samples). The patient harboring the p.A67G variant
inherited it from the father who presented a normal thyroid
gland and normal thyroid function.
In addition, the allelic frequency (patients versus
controls) for two TTF-2 variants already described was
as follows: c.387T>C (p.L129L)—0.83/0.74; c.825C>T
(p.S275S)—0.67/0.66.
3.2. TPO and TG Expression Levels. Paired analysis of tumor
and corresponding normal thyroid samples (possible in 7
cases) revealed a signiﬁcant decrease (P<0.0001) in TPO
and TG expression among the tumor group (Figure 1),
reinforcing previous results [5].
Analysis of TPO and TG expression levels, among
tumors, according to the subtype of molecular alteration
identiﬁed, conducted to the observation that the tumor
sample presenting both the RET/PTC3 rearrangement and
the p.A67G showed the lowest TPO expression level amongst
all tumor samples (Figure 2).
4. Discussion
Thyroid cancer has a very low incidence in the pediatric
population. The yearly incidence of DTC (PTC and FTC),
in the United States, in patients from 5 to 20 years of
age ranged from 0.7 to 14 cases per million, according to
data in the SEER database 1975–2000 [1]. Under the age
of 5, it is extremely rare [7, 8]. Exposition to ionizing
radiation is a signiﬁcant risk factor particularly for papillaryJournal of Oncology 3
Table 1: TTF-1/NKX2-1 and TTF-2/FOXE1: primers and PCR conditions used.
Amplicon Primers (5 –3 ) Annealing temperature (◦C) Expected length (bp)
TTF-1
1sv1 agactcgctcgctcatttgt 58 231
ctccatgcccactttcttgt
1sv2 gcctccactcaagccaatta 62 273
ctccatgcccactttcttgt
2 tgtcgatgagtccaaagcac 62 320
gctgttcctcatggtgtcct
3 ctactgcaacggcaacctg 56 404
cctggcgcttcattttgtag
4 ccagcatgatccacctgac 56 222
gtttgccgtctttcaccag
5 caacaggctcagcagcagt 62 317
gaggagttcaggtgggacag
6 gccaggtatccagcctgtccg 60 210
cggccaggttgttaagaaaa
TTF-2
1 acgatcccctgagctctcc 58 301
tgagcgcgatgtagctgtag
2 tggctaccgtgaaggaagag 55 300
ggatcttgaggaagcagtcg
3 ggcggcatctacaagttcat 58 256
gcatgtaagccgggtaggt
4 ctcggacctctccacctacc 58 300
gaggcaaaggcgcaagag
5 gtcttcggcctggttcct 60 317
gtgcgcccgtagaagtcc
6 gaccacggtggacttctacg 62 244
tccattcctgttcgttctca
(
a
.
u
.
)
TG                                       
Normal
Tumor Mean value
TPO
A67G
A170A
P<0.0001
P<0.0001
Figure 1: mRNA expression of TG and TPO: comparative analysis
between tumors and corresponding normal thyroid tissue (possible
in7cases,referredinTable2as4,5,6,8,9,16,and17).Quantitative
PCR results are expressed as arbitrary units (a.u.) representing x-
fold diﬀerences relative to the reference sample.
TG                                                
RET/PTC3
RET/PTC1
BRAFV600E
Other
A170A
(
a
.
u
.
)
TPO    
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Mean value
Figure 2: mRNA expression of TG and TPO among tumors
according to the molecular alteration identiﬁed. Quantitative PCR
results are expressed as arbitrary units (a.u.) representing x-fold
diﬀerences relative to the reference sample.4 Journal of Oncology
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thyroid cancer, the most common type of DTC [9, 10].
In childhood, the thyroid presents a higher susceptibility
to the carcinogenetic eﬀect of ionizing radiation than in
adulthood [11]. Nonetheless, a large percentage of DTC in
young patients cannot be explained by this external risk
factor.
Common variants on 9q22.33 and 14q13.3 were shown
to predispose to thyroid cancer in European populations [2].
The gene nearest to the 9q22.33 locus is FOXE1 (TTF-2), and
NKX2-1 (TTF-1) is among the genes located at the 14q13.3
locus. Almost at the same time, Landa et al. [12] showed
that the variant rs1867277 within the TTF-2 5 UTR confers
thyroid cancer susceptibility.
We hypothesized that children and adolescents, who
develop thyroid cancer, without a prior exposition to radi-
ation and without a family history of thyroid disease, might
represent a group with a higher susceptibility. Therefore, we
decided to assess the potential contribution of TTF-1 and
TTF-2 genes as sources of genetic susceptibility to thyroid
cancer in this particular group.
Eighteen patients were included in the present study.
Multifocal carcinoma was found in 13/18 (72,2%), extrathy-
roidal extension in 10/18 (55,6%), and neck lymph node
metastases in 12/18 (66,7%). Such a high frequency of
multifocality,asreportedinotherstudies[13],reinforcedthe
hypothesis of a genetic background.
Screening for TTF-1 and TTF-2 variants disclosed two
novel variants in the TTF-2 gene. One variant is a silent
one,theotherpredictsanaminoacidsubstitution,c.200C>G
(p.A67G), located within the forkhead domain and con-
served between species. The former variant was observed
in 1/32 healthy individual, whereas the latter variant was
not observed in the control group. However, the c.200C>G
variant was also present in the patient’s father who had a
normal thyroid and a normal thyroid function. Moreover,
the patient presenting this alteration had also a RET/PTC3
rearrangementsuﬃcienttojustifythePTCphenotype. Thus,
we considered both variants as polymorphisms. A possible
interplay between the RET/PTC3 and the c.200C>G TTF-2
variant cannot be excluded and awaits further clariﬁcation.
The allelic frequencies of the other TTF-2 variants were not
signiﬁcantly diﬀerent between patients and controls.
We assessed the functional consequences of the variants
described herein by comparing the thyroglobulin (TG)
and thyroid peroxidase (TPO) expression among tumors.
Noteworthy,thepatientwiththec.200C>Gvariantpresented
the lowest TPO expression suggesting that this variant might
alter the TPO transcription normally regulated by the TTF-2
transcription factor [14].
Despite the small number of cases, based on present
results, TTF-1 and TTF-2 variants do not seem to contribute
greatly to an earlier age of onset of thyroid cancer.
5. Conclusions
The aim of the study was to investigate whether TTF-1
and TTF-2 variants might contribute to thyroid cancer risk
in children and adolescents. This hypothesis derived from
the fact that two common variants, close from these genes,
known to play an important role for thyroid organogenesis
and diﬀerentiation, have been reported to be associated
with a 5.7-fold increase in the risk of thyroid cancer in
homozygous individuals.
No TTF-1 variant was identiﬁed. For TTF-2,2v a r i a n t s
already identiﬁed had the same allelic frequency in patients
and controls. Two new TTF-2 variants (c.200C>Ga n d
c.510C>A) were identiﬁed in 2 adolescents. The variant
c.510>A (p.A170A) was also identiﬁed in a control sub-
ject. The patient harboring the c.200>G variant (p.A67G)
inherited it from the father who presented a normal thyroid
morphology and normal thyroid function. In addition, the
lattervariantwasassociated,inthepatient,witha RET/PTC3
rearrangement suﬃcient to respond for the neoplastic phe-
notype. Altogether, results suggest that the two new TTF-2
variants are likely to be polymorphisms.
Noteworthy, the c.200C>G variant was associated with
the lowest TPO expression suggesting that this variant might
alter the TPO transcription, normally, regulated by the TTF-
2 transcription factor. Whether this occurred by chance or
inﬂuenced by the RET/PTC3 cannot be excluded.
The frequency of RET/PTC rearrangements and BRAF
mutationsobservedwasinaccordancewithpreviousreports,
thus showing that RET/PTC is the most common genetic
alteration in papillary carcinomas from young patients.
Although limited by the number of patients studied,
our results suggest that TTF-1 and TTF-2 variants do not
make a major contribution to an earlier onset of thyroid
cancer.
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